Raymond James Financial Services Advisors Inc. lowered its stake in shares of Mylan NV (NASDAQ:MYL) by 29.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 83,068 shares of the company’s stock after selling 33,940 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in Mylan were worth $2,276,000 at the end of the most recent reporting period.
A number of other large investors also recently bought and sold shares of MYL. Oregon Public Employees Retirement Fund increased its position in shares of Mylan by 2,715.0% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 6,145,628 shares of the company’s stock worth $224,000 after acquiring an additional 5,927,314 shares in the last quarter. Clearbridge Investments LLC increased its position in shares of Mylan by 69.1% in the third quarter. Clearbridge Investments LLC now owns 4,280,371 shares of the company’s stock worth $156,662,000 after acquiring an additional 1,749,631 shares in the last quarter. BlackRock Inc. increased its position in shares of Mylan by 2.6% in the fourth quarter. BlackRock Inc. now owns 39,965,771 shares of the company’s stock worth $1,095,061,000 after acquiring an additional 1,018,811 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Mylan by 8.7% in the third quarter. Bank of New York Mellon Corp now owns 10,226,277 shares of the company’s stock worth $374,280,000 after acquiring an additional 818,059 shares in the last quarter. Finally, Toronto Dominion Bank increased its position in shares of Mylan by 131.8% in the fourth quarter. Toronto Dominion Bank now owns 1,339,082 shares of the company’s stock worth $36,686,000 after acquiring an additional 761,483 shares in the last quarter. 83.01% of the stock is currently owned by institutional investors.
Several equities research analysts have recently issued reports on the stock. UBS Group reissued a “neutral” rating and issued a $31.00 price objective on shares of Mylan in a research report on Thursday, March 7th. Zacks Investment Research lowered shares of Mylan from a “hold” rating to a “strong sell” rating in a report on Wednesday, March 6th. Credit Suisse Group reaffirmed a “buy” rating and set a $37.00 price target on shares of Mylan in a report on Wednesday, March 6th. Morgan Stanley raised shares of Mylan from an “equal weight” rating to an “overweight” rating and set a $35.00 price target for the company in a report on Wednesday, March 6th. They noted that the move was a valuation call. Finally, Wells Fargo & Co lowered their price target on shares of Mylan from $40.00 to $33.00 and set an “outperform” rating for the company in a report on Wednesday, February 27th. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and fourteen have assigned a buy rating to the stock. Mylan presently has a consensus rating of “Buy” and an average price target of $40.72.
Mylan (NASDAQ:MYL) last announced its quarterly earnings data on Tuesday, February 26th. The company reported $1.30 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.36 by ($0.06). The company had revenue of $3.04 billion for the quarter, compared to analyst estimates of $3.10 billion. Mylan had a return on equity of 19.06% and a net margin of 3.08%. Mylan’s revenue was down 4.8% on a year-over-year basis. During the same period in the prior year, the business earned $1.43 earnings per share. Equities analysts forecast that Mylan NV will post 4.38 earnings per share for the current fiscal year.
In other Mylan news, insider Paul Campbell sold 11,533 shares of the firm’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $27.50, for a total transaction of $317,157.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.81% of the stock is owned by company insiders.
COPYRIGHT VIOLATION NOTICE: This story was published by WKRB News and is the sole property of of WKRB News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://www.wkrb13.com/2019/03/15/mylan-nv-myl-holdings-trimmed-by-raymond-james-financial-services-advisors-inc.html.
Mylan Company Profile
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.
Recommended Story: What is a short straddle?
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.